Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
TRVN Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: January 27, 2025
Report Source: 2024 3rd Quarter Report
Trevena Inc. Stock Analysis TRVN
United States Health Care Nano Cap Report: Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Atlanta, Georgia and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
Read More Trevena Inc (TRVN) Chart
Key Statistics of Trevena Inc (TRVN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.01Volume
1525.00P/E Ratio (TTM)
-52 Week Range
Market Cap
9588.00Avg. Volume
1842.45Dividend Yield
-Financial Metrics & Statements of Trevena Inc (TRVN)
FAQ's for Trevena Inc (TRVN)
- According to Musaffa’s Shariah screening methodology, Trevena Inc (TRVN) is currently classified as NOT HALAL as of January 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Trevena Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Trevena Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Trevena Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Trevena Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Trevena Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.